All Posts By

CND Life Sciences

Response to the S4 Study Results in Neurology

By In the News

A group of international experts responded to the publication of the recent Systemic Synuclein Sampling Study (S4), which found alpha-synuclein to be a specific—but not sensitive—marker of Parkinson’s disease. Their letter details how the study’s methods, rather than the specificity of alpha-synuclein as a marker for Parkinson’s disease, may have produced the results.

Read More